Evvy Company Profile

Background

Evvy, founded in 2020 and headquartered in New York City, is a female-founded biotech startup dedicated to closing the gender health gap by researching and leveraging overlooked female biomarkers, starting with the vaginal microbiome. The company's mission is to provide women and people with vaginas access to comprehensive, personalized healthcare solutions that address the unique challenges in female health. Evvy's primary focus is on developing at-home testing and care platforms that empower individuals to understand and manage their vaginal health effectively.

Key Strategic Focus

Evvy's strategic focus centers on:

Comprehensive At-Home Testing: Offering the first and only at-home metagenomics-based vaginal microbiome test, enabling users to identify and understand the composition of their vaginal microbiome.

Personalized Clinical Care: Providing physician-reviewed results and tailored prescription treatment programs based on individual test outcomes and health histories.

Health Coaching and Education: Delivering 1:1 health coaching and science-backed education to support users throughout their healthcare journey.

Integration of Advanced Technologies: Utilizing metagenomic sequencing and AI-driven data analysis to uncover novel biomarkers and enhance diagnostic accuracy.

Target Markets: Addressing prevalent conditions such as bacterial vaginosis, yeast infections, recurrent urinary tract infections, and exploring links between the vaginal microbiome and broader health outcomes like infertility and preterm birth.

Financials and Funding

Evvy has successfully secured funding to support its growth and innovation:

Seed Funding: Raised $5 million in 2021, led by General Catalyst.

Series A Funding: Secured $14 million in September 2023, led by Left Lane Capital, with participation from General Catalyst, Labcorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue, and Amboy Street Ventures.

Debt Financing: Obtained $10 million in debt financing in March 2025, bringing the total fundraising to nearly $30 million.

The capital is intended to scale access to Evvy's testing and care platform, leverage AI for discovering novel molecular signatures for women's health diagnostics, and validate improved outcomes in fertility, pregnancy, and beyond.

Pipeline Development

Evvy's key developments include:

Vaginal Health Test: Launched in 2021, this at-home test uses metagenomic sequencing to analyze the vaginal microbiome comprehensively.

Expanded PCR Panel: Introduced in 2023, this add-on to the Vaginal Health Test screens for common sexually transmitted infections (STIs) and antibiotic resistance genes.

Clinical Validation: An IRB-approved study demonstrated that 83% of participants moved from dysbiosis to a protective microbiome, and 100% reported symptom improvement after using Evvy's care platform.

Technological Platform and Innovation

Evvy's technological innovations include:

Metagenomic Sequencing: Employing advanced sequencing techniques to identify all bacteria and fungi in the vaginal microbiome from a single swab, providing comprehensive insights.

AI-Driven Data Analysis: Utilizing artificial intelligence to analyze complex datasets, uncover novel biomarkers, and enhance diagnostic precision.

Personalized Treatment Programs: Developing integrative care plans that combine targeted prescription medications with research-backed supplements to restore and maintain a healthy vaginal microbiome.

Leadership Team

Evvy's leadership comprises experienced professionals dedicated to advancing women's health:

Priyanka Jain: Co-Founder & CEO. Former Head of Product at pymetrics, with a background in product development and a commitment to closing the gender health gap.

Laine Bruzek: Co-Founder & COO. Former Team Lead at Google's Creative Lab, bringing expertise in creative strategy and operations.

Pita Navarro: Co-Founder & Chief Science Officer. Former Head of Clinical Research and Operations at Athelas, with extensive experience in clinical research and scientific innovation.

Tanya Jain: Head of Product. Former Senior Product Manager at Ro, specializing in product management and development.

Alyssa Marafino: Head of Growth. Former VP of Growth at Beam, focusing on scaling business operations and market expansion.

Leadership Changes

In January 2023, Evvy appointed Dr. Kate McLean, MD, MPH, FACOG, as its first Chief Medical Officer. Dr. McLean brings extensive experience in obstetrics and gynecology, enhancing Evvy's clinical expertise and guiding its medical initiatives.

Competitor Profile

Market Insights and Dynamics

The women's health diagnostics market is experiencing significant growth, driven by increasing awareness and demand for personalized healthcare solutions. The vaginal health segment, in particular, is expanding as more individuals seek accessible and comprehensive testing options.

Competitor Analysis

Key competitors in the vaginal microbiome testing and women's health diagnostics space include:

Juno Bio: Offers at-home vaginal microbiome testing with personalized reports and recommendations.

uBiome: Provides microbiome testing services, including vaginal microbiome analysis, though faced operational challenges in recent years.

Thryve: Focuses on gut microbiome testing but has expanded into vaginal health, offering insights and personalized recommendations.

Seed Health: Specializes in probiotics and microbiome health, offering products aimed at supporting gut and vaginal health.

Evvy differentiates itself through its comprehensive care platform that combines advanced metagenomic sequencing, personalized treatment plans, and dedicated health coaching, providing a holistic approach to vaginal health.

Strategic Collaborations and Partnerships

Evvy has established collaborations to enhance its offerings:

Medical Advisory Board: Comprises leading OB/GYNs and scientists from institutions like UCSF, Stanford, and the Cleveland Clinic, guiding research and clinical practices.

Laboratory Partnerships: Works with CLIA/CAP-certified labs to ensure high-quality testing and accurate results.

Investor Partnerships: Secured funding from prominent investors such as Left Lane Capital and General Catalyst, supporting growth and innovation initiatives.

Operational Insights

Evvy's strategic considerations include:

Market Positioning: Positioned as a leader in precision women's healthcare, focusing on data-driven, personalized solutions.

Competitive Advantages: Offers a unique combination of advanced testing, personalized care, and educational support, setting it apart from competitors.

Scalability: Plans to expand access to its platform, integrate with healthcare systems, and explore additional applications of its technology in areas like fertility and pregnancy outcomes.